Free Trial

Vicapsys Life Sciences Q3 2023 Earnings Report

Vicapsys Life Sciences logo
$2.05 0.00 (0.00%)
As of 01/21/2025

Vicapsys Life Sciences EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Vicapsys Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vicapsys Life Sciences Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Vicapsys Life Sciences Earnings Headlines

British Science Week - Teaching Resources
Stunning Trump Manhattan Project Now Underway
Just as I predicted, President Trump announced his #1 move during his first 100 days... His allies are calling it Trump’s Manhattan Project.
Anavex Life Sciences Corp AVXL
VICP - Vicapsys Life Sciences, Inc.
See More Vicapsys Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vicapsys Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vicapsys Life Sciences and other key companies, straight to your email.

About Vicapsys Life Sciences

Vicapsys Life Sciences (OTCMKTS:VICP) focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.

View Vicapsys Life Sciences Profile

More Earnings Resources from MarketBeat